Accession Number:

ADA460468

Title:

Anti-Cancer Drug Discovery Using Synthetic Lethal Chemogenetic (SLC) Analysis

Descriptive Note:

Annual summary rept. 1 Jul 2003-30 Jun 2006

Corporate Author:

MOUNT SINAI HOSPITAL TORONTO (ONTARIO)

Personal Author(s):

Report Date:

2006-07-01

Pagination or Media Count:

13.0

Abstract:

I am developing a novel cell-based small-molecule screening approach that can identify inhibitors of any non-essential protein function through a surrogate synthetic lethal phenotype in the bakers yeast, Saccharomyces cerevisiae. Synthetic lethality SL is a form of genetic enhancement in which two mutations are lethal in combination, but the corresponding individual mutants are viable. Thus, a sensitized yeast strain carrying a mutation that is synthetic lethal with a gene of interest will be inviable in the presence of a chemical inhibitor of the target protein. Systematic genome-wide genetic screens can simultaneously determine all the synthetic lethal genetic interactions for a given gene deletion in yeast. I will adopt this strategy to determine the SL partners for the yeast genes SCH9, the yeast homologue of the human oncogene AKT, and TEP1, the yeast equivalent of the human tumor suppressor PTEN. Selected confirmed synthetic lethal mutants will be used as sensitized strains to screen a commercial small-molecule library for inhibitors of the corresponding proteins. I have developed a yeast-based high-throughput screening platform to screen the Maybridge small-molecule library. Compounds derived from the initial chemical genetic screen will be validated biochemically and, ultimately, tested on mammalian cells for activity against the human homologues.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE